Skip to main content
SpringerLink
Log in
Book cover

Serous Effusions pp 29–48Cite as

Lung Carcinoma

  • Chapter
  • First Online:

  • 535 Accesses

Abstract

Lung carcinoma remains the most common source of malignant effusions. A malignant effusion would upstage a lung tumor of any size to stage IV and significantly affect the treatment modality. It may also be the first manifestation of the disease, and a definitive diagnosis can spare the patient additional more morbid diagnostic procedures. This chapter reviews the epidemiology, the clinical presentation, and the morphologic features diagnostic of adenocarcinoma, squamous cell carcinoma, and small cell carcinoma. The differential diagnoses and diagnostic pitfalls are discussed in detail along with the utilization of ancillary techniques, particularly the up-to-date immunohistochemical stains relevant for establishing a definitive diagnosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ferlay J, Soerjonataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.1 cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2014. http://globocan.iarc.fr. Accessed 16 Jan 2015.

    Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Fewer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2014, Bethasda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2014/, bases on November 2016 SEER data submission, posted to the SEER web site, April 2017.

  3. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ. 1992;120:45–173.

    Google Scholar 

  4. Travis WD, Brambilla E, Burke A, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press; 2015.

    Google Scholar 

  5. Porcel JM, Esquerda A, Vives M, Bilsa S. Etiology of pleural effusion: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50:161–5.

    Article  PubMed  Google Scholar 

  6. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20:654–9.

    Article  PubMed  Google Scholar 

  7. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905–9.

    Article  CAS  PubMed  Google Scholar 

  8. DiBonito L, Falconieri G, Colautti I, Bonifacio D, Dudine S. The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol. 1992;36:329–32.

    PubMed  CAS  Google Scholar 

  9. Renshaw AA, Madge R, Sugarbaker DJ, Swanson S. Malignant pleural effusions after resection of pulmonary adenocarcinoma. Acta Cytol. 1998;42:1111–5.

    Article  CAS  PubMed  Google Scholar 

  10. Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J. 1997;112:242S–8S.

    Google Scholar 

  11. Eberhardt WE, Mitchell A, Crowley L, et al. The IASLC lung cancer staging project: proposals for the revisions of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(110):1515–22.

    Article  PubMed  Google Scholar 

  12. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung. In: Amin MB, editor. AJCC cancer staging manual. 8th ed. Cham: Springer; 2017.

    Google Scholar 

  13. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Pastorelli D. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol. 2010;33:420–3.

    Article  PubMed  Google Scholar 

  14. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 1990;154:487–92.

    Article  CAS  PubMed  Google Scholar 

  15. Azzopardi M, Porcel JM, Koegelenberg CF, Lee YCG, Fysh ETH. Current controversies in the management of malignant pleural effusions. Semin Respir Crit Care Med. 2014;35:723–31.

    Article  PubMed  Google Scholar 

  16. Yoneda KY, Mathur PN, Gasparini S. The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer: Part III: diagnosis and management of malignant pleural effusions. Clin Lung Cancer. 2007;8(9):535–47.

    Article  CAS  PubMed  Google Scholar 

  17. Ozcakar B, Martinez CH, Morice RC, et al. Does pleural fluid appearance really matter? The relationship between fluid appearance and cytology, cell counts, and chemical laboratory measurements in pleural effusions of patients with cancer. J Cardiothorac Surg. 2010;5:63.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235–50.

    Article  PubMed  Google Scholar 

  19. Kimura M, Tojo T, Naito H, Nagata Y, Kawai N, Taniguchi S. Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination. Interact Cardiovasc Thorac Surg. 2010;10:568–71.

    Article  PubMed  Google Scholar 

  20. Sahn SA. Pleural effusion in lung cancer. Clin Chest Med. 1982;3:443–52.

    PubMed  CAS  Google Scholar 

  21. Bedrossian CWM, editor. Malignant effusions: a multimodal approach to cytologic diagnosis. New York: Igaku-Shoin; 1994.

    Google Scholar 

  22. Tao LC, editor. Cytopathology of malignant effusions. Chicago: ASCP Press; 1996.

    Google Scholar 

  23. Michael CW, Bedrossian CWM, Chhieng D. Effusion cytology. In: Michael CW, editor. Papanicolaou society of cytopathology monograph series. New York, NY: Cambridge University Press; 2015.

    Google Scholar 

  24. Tang P, Vatsia SK, Teichberg S, Kahn E. Pulmonary adenocarcinoma simulating malignant mesothelioma. Arch Pathol Lab Med. 2001;125:1598–600.

    PubMed  CAS  Google Scholar 

  25. Kaur G, Nijhawan R, Gupta N, Singh N, Rajwanshi A. Pleural fluid cytology samples in cases of suspected lung cancer: an experience from tertiary care center. Diagn Cytopathol. 2017;45:195–201.

    Article  PubMed  Google Scholar 

  26. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol. 1987;18:67–74.

    Article  CAS  PubMed  Google Scholar 

  27. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol. 1994;11:237–45.

    Article  CAS  PubMed  Google Scholar 

  28. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer. 2001;93:293–308.

    Article  CAS  PubMed  Google Scholar 

  29. Westfall DE, Fan X, Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn Cytopathol. 2010;38:9–14.

    PubMed  Google Scholar 

  30. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer. 2001;93:68–72.

    Article  CAS  PubMed  Google Scholar 

  31. Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol. 1999;112:75–89.

    Article  CAS  PubMed  Google Scholar 

  32. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol. 1994;10:130–4.

    Article  CAS  PubMed  Google Scholar 

  33. Lv M, Leng J-H, Hao Y-Y, Sun Y, Cha N, Wu G-P. Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer. Diagn Cytopathol. 2015;43:527–31.

    Article  PubMed  Google Scholar 

  34. Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32:529–36.

    Article  CAS  PubMed  Google Scholar 

  35. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol. 1997;21:1409–19.

    Article  CAS  PubMed  Google Scholar 

  36. Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol. 1989;20:53–7.

    Article  CAS  PubMed  Google Scholar 

  37. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19–9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 1998;84:101–8.

    Article  CAS  PubMed  Google Scholar 

  38. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol. 1999;20:125–30.

    Article  CAS  PubMed  Google Scholar 

  39. Han AC, Filstein MR, Hunt JV, Soler AP, Knudsen KA, Salazar H. N-cadherin distinguishes pleural mesotheliomas from lung adeno-carcinomas: a ThinPrep immunocytochemical study. Cancer. 1999;87:83–6.

    Article  CAS  PubMed  Google Scholar 

  40. Schofield K, D’Aquila T, Rimm DL. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids. Cancer. 1997;81:293–8.

    Article  CAS  PubMed  Google Scholar 

  41. Saqi A, Yun SS, Yu GH, et al. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagn Cytopathol. 2005;33:65–70.

    Article  PubMed  Google Scholar 

  42. Chu PG, Arber DA, Weiss LM. Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. Am J Clin Pathol. 2003;120:64–70.

    Article  PubMed  Google Scholar 

  43. O’Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254–63.

    Article  PubMed  Google Scholar 

  44. Llinares K, Escande F, Aubert S, et al. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol. 2004;17:150–7.

    Article  PubMed  Google Scholar 

  45. Takezawa C, Takahashi H, Fujishima T, et al. Assessment of differentiation in adenocarcinoma cells from pleural effusion by peripheral airway cell markers and their diagnostic values. Lung Cancer. 2002;38:273–81.

    Article  PubMed  Google Scholar 

  46. Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 2007;109:933–8.

    Article  CAS  PubMed  Google Scholar 

  47. Gomez-Fernandez C, Jorda M, Delgado PI, Ganjei-Azar P. Thyroid transcription factor 1: a marker for lung adenocarcinoma in body cavity fluids. Cancer. 2002;96:289–93.

    Article  CAS  PubMed  Google Scholar 

  48. Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol. 2007;35:370–5.

    Article  PubMed  Google Scholar 

  49. Tan D, Zander DS. Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update. Int J Clin Exp Pathol. 2008;1:19–31.

    PubMed  PubMed Central  CAS  Google Scholar 

  50. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238–42.

    Article  CAS  PubMed  Google Scholar 

  51. Pomplun S, Wotherspoon AC, Shah G, Goldstraw P, Ladas G, Nicholson AG. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. Histopathology. 2002;40:152–8.

    Article  CAS  PubMed  Google Scholar 

  52. Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract. 2005;201:579–86.

    Article  CAS  PubMed  Google Scholar 

  53. Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol. 2007;35:493–7.

    Article  PubMed  Google Scholar 

  54. El-Hag M, Schmidt L, Roh M, Michael CW. Utility of TTF-1 and Napsin-A in the work up of malignant effusions. Diagn Cytopathol. 2016;44:299–304.

    Article  PubMed  Google Scholar 

  55. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962–72.

    Article  CAS  PubMed  Google Scholar 

  56. Li HC, Schmidt L, Greenson JK, Chang AC, Myers JL. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma: case report and review of literature. Am J Clin Pathol. 2009;131:129–33.

    Article  PubMed  Google Scholar 

  57. Spriggs AI, Boddington MM. Oat-cell bronchial carcinoma. Identification of cells in pleural fluid. Acta Cytol. 1976;20:525–9.

    PubMed  CAS  Google Scholar 

  58. Spieler P, Gloor F. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids. Comparison with the diagnostic accuracy on small histologic biopsies. Acta Cytol. 1985;29:753–67.

    PubMed  CAS  Google Scholar 

  59. Smith R, Nguyen GK. Unusual cytologic manifestation of small-cell lung cancer in associated pleural effusion. Diagn Cytopathol. 2004;30:266–7.

    Article  PubMed  Google Scholar 

  60. Salhadin A, Nasiell M, Nasiell K, et al. The unique cytologic picture of oat cell carcinoma in effusions. Acta Cytol. 1976;20:298–302.

    PubMed  CAS  Google Scholar 

  61. Khunamornpong S, Siriaunkgul S, Suprasert P. Cytology of small-cell carcinoma of the uterine cervix in serous effusion: a report on two cases. Diagn Cytopathol. 2001;24:253–5.

    Article  CAS  PubMed  Google Scholar 

  62. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13:174–84.

    Article  PubMed  Google Scholar 

  63. DeLellis RA. The neuroendocrine system and its tumors: an overview. Am J Clin Pathol. 2001;115(Suppl):S5–S16.

    PubMed  Google Scholar 

  64. Chhieng DC, Ko EC, Yee HT, Shultz JJ, Dorvault CC, Eltoum IA. Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study. Diagn Cytopathol. 2001;25:356–60.

    Article  CAS  PubMed  Google Scholar 

  65. Cerilli LA, Ritter JH, Mills SE, Wick MR. Neuroendocrine neoplasms of the lung. Am J Clin Pathol. 2001;116(Suppl):S65–96.

    PubMed  Google Scholar 

  66. Smith-Purslow MJ, Kini SR, Naylor B. Cells of squamous cell carcinoma in pleural, peritoneal and pericardial fluids. Origin and morphology. Acta Cytol. 1989;33:245–53.

    PubMed  CAS  Google Scholar 

  67. Huang CC, Michael CW. Cytomorphological features of metastatic squamous cell carcinoma in serous effusions. Cytopathology. 2014;25:112–9.

    Article  CAS  PubMed  Google Scholar 

  68. Nieto-Llanos S, Vera-Roman JM. Squamous cell carcinoma of the bladder with metastasis diagnosed cytologically in a pleural effusion. Acta Cytol. 1999;43:1191–2.

    PubMed  CAS  Google Scholar 

  69. Hoda SA, Rosen PP. Cytologic diagnosis of metastatic penile carcinoma in pleural effusion. Arch Pathol Lab Med. 1992;116:198–9.

    PubMed  CAS  Google Scholar 

  70. Gamez RG, Jessurun J, Berger MJ, Pambuccian SE. Cytology of metastatic cervical squamous cell carcinoma in pleural fluid: report of a case confirmed by human papillomavirus typing. Diagn Cytopathol. 2009;37:381–7.

    Article  PubMed  Google Scholar 

  71. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36:20–5.

    Article  PubMed  Google Scholar 

  72. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38:1–16.

    Article  CAS  PubMed  Google Scholar 

  73. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417–28.

    Article  PubMed  Google Scholar 

  74. Li Q, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion. Semin Diagn Pathol. 2006;23:15–9.

    Article  PubMed  Google Scholar 

  75. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30:878–82.

    Article  PubMed  Google Scholar 

  76. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔN063) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405–15.

    Article  CAS  PubMed  Google Scholar 

  77. Alexander M, Chiaffarano J, Zhou F, Cangiarella J, Yee-Chang M, Simsir A. Can p40 (polyclonal) replace p63 (Clone 4A4) in the cytologic diagnosis of pulmonary non-small cell carcinoma? Am J Clin Pathol. 2017;147:580–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA

    Claire W. Michael

Authors
  1. Claire W. Michael
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire W. Michael .

Editor information

Editors and Affiliations

  1. Department of Pathology, The Norwegian Radium Hospital Oslo University Hospital , Oslo, Norway

    Ben Davidson

  2. Department of Pathology, School of Medicine, Koç University, Istanbul, Turkey

    Pinar Firat

  3. UH Cleveland Medical Center, Case Western Reserve University, UH Clevel and Medical Center, Cleveland, Ohio, USA

    Claire W. Michael

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Michael, C.W. (2018). Lung Carcinoma. In: Davidson, B., Firat, P., Michael, C. (eds) Serous Effusions. Springer, Cham. https://doi.org/10.1007/978-3-319-76478-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-76478-8_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-76477-1

  • Online ISBN: 978-3-319-76478-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation